Pacific Biosciences (NASDAQ:PACB) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish |
---|
Total Ratings | 3 | 2 | 5 | 0 | 0 |
Last 30D | 0 | 0 | 1 | 0 | 0 |
1M Ago | 1 | 2 | 3 | 0 | 0 |
2M Ago | 1 | 0 | 1 | 0 | 0 |
3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.4, a high estimate of $12.00, and a low estimate of $2.00. Experiencing a 50.56% decline, the current average is now lower than the previous average price target of $8.90.
![price target chart](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240514/0-000ed16b5384456bdf6d527a11f9c814-0-1e1071f268ea052ddfa0864255da39a4.webp/bigjpg)
Interpreting Analyst Ratings: A Closer Look
A comprehensive examination of how financial experts perceive Pacific Biosciences...
Pacific Biosciences(納斯達克股票代碼:PACB)在上個季度接受了10位分析師的分析,揭示了從看漲到看跌的一系列觀點。
下表總結了他們最近的評級,展示了過去30天內不斷變化的情緒,並將...